Department of Biomedical Engineering, University of Minnesota , Minneapolis, MN, USA.
Tissue Eng Part C Methods. 2010 Jun;16(3):459-67. doi: 10.1089/ten.TEC.2009.0112.
Current methods for measuring collagen content in engineered tissues are incompatible with monitoring of collagen production because they require destruction of the tissue. We have implemented a luciferase-based strategy to monitor collagen production noninvasively. Fibrin-based tissue constructs made using vascular smooth muscle cells stably transfected with a collagen I promoter/luciferase transgene developed with collagen content comparable to control cells, but could be imaged noninvasively to follow collagen transcription during tissue growth in vitro. We showed that these cells reported collagen I production at the transcriptional level in response to the growth factor transforming growth factor-beta1 and fibrinolytic inhibition by epsilon-aminocaproic acid and that these changes were consistent with changes at the mRNA and protein levels. As these cells report collagen changes instantly and without tissue destruction, they will facilitate construct optimization using multiple stimuli to produce functional engineered tissues.
目前用于测量工程组织中胶原蛋白含量的方法与监测胶原蛋白产生不兼容,因为它们需要破坏组织。我们已经实施了一种基于荧光素酶的策略,可非侵入性地监测胶原蛋白的产生。使用血管平滑肌细胞稳定转染胶原蛋白 I 启动子/荧光素酶转基因的纤维蛋白组织构建体可与对照细胞相比,具有可比的胶原蛋白含量,但可以进行非侵入性成像,以在体外组织生长过程中跟踪胶原蛋白转录。我们表明,这些细胞在转录水平上报告胶原蛋白 I 的产生,以响应生长因子转化生长因子-β1 和 ε-氨基己酸的纤维蛋白溶解抑制,并且这些变化与 mRNA 和蛋白质水平的变化一致。由于这些细胞即时报告胶原蛋白的变化而不破坏组织,因此它们将促进使用多种刺激物优化构建体以产生功能性工程组织。